Methylprednisolone, intravenous immunoglobulin, tocilizimab or anakinra for children with Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS CoV-2 (PIMS-TS, MIS-C) – report from a randomised, controlled, open-label, platform trial

Samankaltaisia teoksia

• Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
  Tekijä: RECOVERY Collaborative Group
  Julkaistu: (2024)
• The trials of anakinra.
  Tekijä: Burls, A, et al.
  Julkaistu: (2004)
• A national consensus management pathway for Paediatric Inflammatory Multisystem Syndrome - Temporally associated with SARS-CoV-2 (PIMS-TS): The results of a national Delphi process
  Tekijä: Harwood, R, et al.
  Julkaistu: (2020)
• High dose intravenous methylprednisolone in the treatment of severe acute respiratory syndrome.
  Tekijä: Mishra, S, et al.
  Julkaistu: (2004)
• Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.
  Tekijä: Barnes, D, et al.
  Julkaistu: (1997)